RARS1 and hepatocellular carcinoma: Together, these results indicate that AH-6809 acts as a potential inhibitor of RARS1, effectively suppressing hepatocellular carcinoma cell proliferation, migration, and invasion, thereby highlighting its therapeutic potential in targeting RARS1-driven tumor progression.